September 18, 2013
The European Commission's Seventh Framework Program will award $801,360 throughout three years to scientific software company Qlucore to develop algorithms for use in personalizing hepatitis C treatment. The company will work on mathematical and statistical algorithms for integrating information from genetic, proteomic, and clinical research data to provide clinicians with a mobile application that could be used at the point of care. Pharmaceutical companies currently are developing new hepatitis C drugs that would lead to more genetic and clinical variables to evaluate for patients and create a need for tools that could assist clinicians in prescribing custom treatments for each patient.
09.16.2013; Ryan McBride
No comments have been made.
|Using Saliva as Lube Can Cause Rectal Gonorrhea|
|This Week in HIV Research: Enzyme May Reduce Cardiovascular Disease Risk, and New Insights Into an HIV Vaccine|
|This Week in HIV Research: Determinants of Cognitive Impairment, and Discovery of 'Teenage' Broadly Neutralizing Antibody|
|FDA Approves Descovy, an Updated Version of Truvada -- But Not for PrEP|
|What Should the Next U.S. President Do to Advance the Fight Against HIV?|